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HDL-associated estradiol stimulates endothelial NO synthase
and vasodilation in an SR-BI–dependent manner
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Cardiovascular diseases remain the leading cause of death in the United States. Two factors associated with a
decreased risk of developing cardiovascular disease are elevated HDL levels and sex — specifically, a decreased risk is
found in premenopausal women. HDL and estrogen stimulate eNOS and the production of nitric oxide, which has
numerous protective effects in the vascular system including vasodilation, antiadhesion, and anti-inflammatory effects.
We tested the hypothesis that HDL binds to its receptor, scavenger receptor class B type I (SR-BI), and delivers estrogen
to eNOS, thereby stimulating the enzyme. HDL isolated from women stimulated eNOS, whereas HDL isolated from men
had minimal activity. Studies with ovariectomized and ovariectomized/estrogen replacement mouse models demonstrated
that HDL-associated estradiol stimulation of eNOS is SR-BI dependent. Furthermore, female HDL, but not male HDL,
promoted the relaxation of muscle strips isolated from C57BL/6 mice but not SR-BI null mice. Finally, HDL isolated from
premenopausal women or postmenopausal women receiving estradiol replacement therapy stimulated eNOS, whereas
HDL isolated from postmenopausal women did not stimulate eNOS. We conclude that HDL-associated estrodial is
capable of the stimulating eNOS. These studies establish a new paradigm for examining the cardiovascular effects of
HDL and estrogen.
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Introduction
The development of cardiovascular diseases is a mul-
tifactorial process that is influenced by both genetic
and environmental factors. Two factors that modu-
late the development of cardiovascular diseases are
HDL and estradiol (1–3). Both HDL and estradiol
can promote the stimulation of eNOS and the sub-
sequent generation of nitric oxide (4–8). Nitric oxide
is a critical player in the physiology and pathophysi-
ology of the vascular system and is thought to be
involved in preventing the oxidation of lipoproteins
(9), preventing the adhesion of monocytes to the
endothelium (10, 11), downregulating inflammatory
mediators (10, 11), and promoting vessel vasodila-
tion (12, 13). Our current studies have focused on
how HDL and estradiol interact to stimulate
endothelial nitric oxide synthase and the generation
of nitric oxide.
Numerous studies have demonstrated that HDL is
cardioprotective and lowers the risk of developing car-
diovascular disease (14–16). A large part of the protec-
tive effects of HDL is thought to be due to the role
HDL plays in reverse cholesterol transport (17, 18).
HDL can lower total plasma cholesterol levels by trans-
porting cholesterol from the peripheral tissues to the
liver. HDL binds to a receptor called scavenger receptor
class B type I (SR-BI) in the liver and subsequently
delivers the sterol to hepatocytes for excretion as bile or
recycling into other lipoprotein particles (19, 20). Our
previous studies demonstrated that SR-BI was also
expressed in endothelial cells and localized to plasma
membrane caveolae (5, 21). This led to the concept that
HDL and SR-BI also may affect the vascular system
independently of their role in decreasing plasma cho-
lesterol. In a series of studies, we demonstrated that
HDL, in a SR-BI dependent manner, could protect
caveolae from the loss of cholesterol (21) and that HDL
can promote the stimulation of caveola-localized eNOS
by a mechanism involving ceramide (5). Independent
work by Yuhanna et al. (4) demonstrated that HDL
could promote the activation of eNOS and vessel dila-
tion in an SR-BI–dependent manner.
Premenopausal women have a lower risk of develop-
ing cardiovascular disease than similarly aged men
(22–24). The mechanism(s) that afford women pro-
tection from cardiovascular disease are not under-
stood, although a considerable amount of research has
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focused on the role of estradiol in mediating some of
the protection. Even though the utility of estradiol
replacement therapy in treating cardiovascular disease
is controversial, many mechanistic studies have
demonstrated an important role for estradiol in the
normal physiology of the vascular system (2, 25, 26).
Relevant to our current study, estradiol stimulates
eNOS and increases the production of nitric oxide
independently of nuclear events (7, 27, 28). Chambliss
et al. (7) demonstrated that estrogen receptors were
localized to plasma membrane caveolae and that the
addition of exogenous estradiol could stimulate
eNOS. In addition, Haynes et al. (29) demonstrated
that estrogen activates akt kinase, which subsequent-
ly phosphorylates and activates eNOS. The difficulties
with previous studies arise in demonstrating specifici-
ty and physiological relevance, because the effects of
estradiol on eNOS activity are usually determined by
adding pharmacological doses of estradiol to cells in
culture, using BSA as a carrier. The physiological car-
rier in the plasma that is responsible for the delivery of
estradiol to eNOS has not been elucidated.
SR-BI and eNOS are both localized to caveolae in
endothelial cells (5, 21), and SR-BI is known to facili-
tate the uptake of sterols into cells (19, 20). Therefore,
we hypothesized that estradiol associated with plas-
ma HDL is targeted to eNOS by the interaction of
HDL with SR-BI in caveolae. The data demonstrate
that estradiol associated with HDL stimulates eNOS
and vessel relaxation.
Methods
Materials. M199, basal medium Eagle vitamin mix, fetal
bovine serum, glutamine, trypsin-EDTA, and peni-
cillin/streptomycin were from Life Technologies, Inc.
(Grand Island, New York, USA). [3H]arginine (specific
activity, 51 Ci/mmol) was from New England Nuclear
(Boston, Massachusetts, USA). Bradford reagent was
purchased from BioRad (Hercules, California, USA).
The mouse feed was obtained from Harlan Tekland
(Madison, Wisconsin, USA). Dowex AG50WX-8 and
Celite 545 were from Sigma-Aldrich (St. Louis, Mis-
souri, USA). The Ultra-Sensitive Estradiol RIA kit was
from Diagnostic System Laboratories Inc. (Webster,
Texas, USA). Human serum was obtained from the
American Red Cross (Lexington, Kentucky, USA). Qual-
ity Control Biochemicals (St. Louis, Missouri, USA) gen-
erated the custom-made SR-BI blocking antibody (5).
[125I]Na (1 mCi/ml) and [2,4,6,7-3H]estradiol (87
Ci/mmol) were purchased from New England Nuclear.
Cell culture. Human microvascular endothelial cells
(CDC.EU/HMEC-1 from the National Center for Infec-
tious Diseases) were cultured in M199 medium sup-
plemented with 100 U/ml penicillin/streptomycin,
0.5% (v/v) L-glutamine, BME vitamin mix (1 ml/100 ml
M199), BME amino acid mix (1 ml/100 ml M199), and
10% (v/v) fetal bovine serum. On day 0, 5,000 cells were
placed into 12-well plates and used on day 3 at approx-
imately 60% confluency.
Activation of NOS in intact cells. NOS activation was
determined in intact cells as previously described (21,
30). Briefly, the cells were plated into 12-well plates at
5,000 cells per well and grown to 60% confluency. The
medium was replaced with serum-free medium for 16
hours and the cells then placed for 2 hours in phos-
phate-buffered saline at 37°C. After the preincuba-
tion period, the PBS was removed from the wells and
replaced with 400 µl of PBS containing 0.75 µCi/ml
[3H]L-arginine. The cells were incubated at 37°C for
15 minutes with the indicated treatments. The NOS
reaction was terminated by adding 500 µl of ice-cold
1 N trichloroacetic acid (TCA) to each well. The cells
were freeze-fractured twice in liquid nitrogen for 2
minutes with thawing at 37°C for 5 minutes and
scraped with a rubber spatula. The contents of each
well were transferred to ice-cold glass test tubes. Ether
extraction was performed three times with water-sat-
urated ether to remove the TCA. The samples were
neutralized with 1.5 ml of 25 mM HEPES (pH 8)
applied to Dowex AG50WX-8 (Tris form) columns and
eluted with 1 ml of 40 mM HEPES buffer (pH 5.5)
containing 2 mM EDTA and 2 mM EGTA. [3H]L-cit-
rulline was collected in scintillation vials and quanti-
fied by liquid scintillation counting. In individual
experiments performed in 12-well plates, 3 wells were
used for each treatment group. Findings were con-
firmed in at least six independent experiments. NOS
activation in the intact cells was inhibited by 1 mM
nitro-L-arginine methyl ester (over 99% of NOS activ-
ity inhibited). To ensure that the treatments did not
affect the loading of the cells with [3H]L-arginine, the
amount of [3H]L-arginine associated with the cells was
determined. The cells contained 220,000 ± 9,184 dis-
integrations per minute per well of [3H]L-arginine
independently of the treatment. For the estrogen
antagonist assays, 10 µM of ICI 182,780 was added to
the HDL and [3H]L-arginine mixture. The mixture was
then incubated with cells for 15 minutes, the reaction
was stopped with TCA, and the cells were processed
to quantify the amount of [3H]L-citrulline generated.
Lipoproteins. VLDL (density, less than 1.006 g/ml), LDL
(density, 1.019–1.05 g/ml), and HDL (density,
1.063–1.21 g/ml) were isolated from human or mouse
plasma by sequential density gradient ultracentrifuga-
tion as described (31). SDS-PAGE and Coomassie stain-
ing were used to assay the purity of each lipoprotein
fraction. HDL, LDL, and BSA were loaded with estradi-
ol by a method similar to that used to label HDL with
cholesteryl ester (32). In brief, estradiol (1–50 mg) was
dried onto 100 mg of Celite 545 and then incubated
with purified HDL, LDL, or BSA for 18 hours at 37°C.
At the end of the incubation, Celite was removed by cen-
trifugation through 0.02 µm filters. The HDL, LDL, and
BSA were then reisolated by ultracentrifugation to
ensure that unincorporated estradiol was removed.
Control HDL, LDL, and BSA were treated identically,
with the exception that estradiol was not added to the
Celite. HDL was labeled with 125I as described (33).
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Estradiol quantification. The amount of estradiol asso-
ciated with HDL, LDL, or BSA was determined by first
extracting lipids by solid-phase extraction using an
Oasis HLB glass cartridge (Waters, Milford, Massachu-
setts, USA). The sample was diluted 1:1 (v/v) with gla-
cial acetic acid and applied to the column. The column
was washed with 40% methanol in water and the lipid
eluted with 10% methyl butyl ether. The amount of
estradiol in the eluent was quantified by radioim-
munoassay using a commercially available kit (Ultra-
Sensitive Estradiol RIA) according to the manufactur-
er’s instructions. Control experiments confirmed the
linearity of the assay between the range of 4 pg/200 µl
and 150 pg/200 µl.
Hormone replacement. Eight-week-old mice (C57BL/6)
were ovariectomized to eliminate endogenous ovarian
steroids (34). Both female and male mice were then
implanted subcutaneously with a Silastic capsule
(inner/outer diameter, 0.062 in/0.125 in; volume, 0.035
ml) containing 17-β-estradiol (180 µg/ml) in sesame
oil. The Silastic capsules consistently releases hormone
over 10 days, producing stable plasma levels of 17-β-
estradiol (31 ± 13 pg/ml) (34). Age- and sex-matched
animals were used throughout the studies.
Arterial relaxation studies. The direct relaxation effect of
HDL on arterial vessels was evaluated in mice spiral
femoral artery strips (150 µm in width, 3 mm in length,
and about 30–40 µm in thickness). Femoral arteries were
removed from 3-month-old male C57BL/6 or SR-BI null
mice. Isometric tension was measured at 24°C with a
force transducer as previously described (35). After equi-
libration and submaximal precontraction with 5-hy-
droxytryptamine (30 nM), relaxation to 1 µM acetyl-
choline was tested to confirm the integrity of the
endothelium. After washing, the strips were again con-
tracted with 5-hydroxytryptamine, and the effects of
HDL were assessed. At the completion of the experiment,
the relaxation response to acetylcholine was confirmed.
In experiments in which the endothelium was denuded,
the integrity of the smooth muscle was confirmed by
normal amplitude of contraction to endothelin and nor-
mal amplitude of relaxation to sodium nitroprusside.
Results
Female HDL but not male HDL stimulates eNOS. To deter-
mine if female and male HDL had a different capacity
to stimulate eNOS, we isolated HDL, LDL, and VLDL
from male and female human serum and from male
and female mouse serum (31). We then used our estab-
lished human microvascular endothelial (HME) cell
system to assay the ability of the isolated lipoproteins
to stimulate eNOS in live, intact cells (5, 21). HME cells
were incubated with 0.75 µCi/ml of [3H]arginine to
label the intracellular arginine pool. Without removal
of the radiolabel, the cells were then incubated with
buffer only or 10 µg/ml of HDL, LDL, or VLDL for 15
minutes at 37°C. In addition, another set of cells was
treated with 1 µg/ml of ionomycin, a calcium iono-
phore, to determine maximal eNOS stimulation. The
cells were then processed to quantify the amount of
[3H]arginine converted to [3H]citrulline as a measure of
enzymatic activity (Figure 1). Control experiments with
1 mM L-NNA, an eNOS inhibitor, demonstrated that
over 99% of the generated citrulline was due to eNOS
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Figure 1
HDL isolated from female subjects stimulates the production of nitric
oxide. HDL, LDL, and VLDL were isolated from young, reproductively
competent female humans (a) and mice (b) and age-matched male
humans (a) and mice (b) (31). The freshly isolated lipoproteins (10
µg/ml) were incubated with human microvascular endothelial cells
that had been prelabeled with 0.75 µCi/ml of [3H]arginine for 15
minutes at 37°C (21). An additional set of cells was treated with 1
µg/ml of ionomycin to determine the maximal eNOS stimulation.
The cells were then washed, lysed, and extracted, and radiolabeled
arginine was separated from radiolabeled citrulline using an ion-
exchange column. Each experiment included controls, using 1 mM
L-NNA to demonstrate that over 99% of the generated citrulline was
due to eNOS activity (data not shown). In (c), a concentration curve
of the effect of female HDL on eNOS activity is shown. The data are
from six to eight independent experiments, with triplicate measure-
ments in each experiment (mean ± SE).
activity (data not shown). HDL (10 µg/ml) isolated
from women (Figure 1a) and female mice (Figure 1b)
stimulated eNOS to the same extent as ionomycin.
Maximal stimulation of eNOS was achieved with 1
µg/ml of HDL (Figure 1c). In contrast, HDL isolated
from both men and male mice only weakly stimulated
eNOS. The LDL and VLDL lipoprotein fractions iso-
lated from both species and sexes did not stimulate
eNOS. Even at high concentrations (500 µg/ml), male
HDL or the LDL and VLDL fractions were unable to
stimulate eNOS (data not shown).
The stimulation of eNOS by female HDL requires SR-BI. To
determine if the ability of female HDL to stimulate
eNOS activity was dependent on SR-BI, we used SR-BI
blocking antibodies and HME cells as we have done
previously (21). HME cells were pretreated with buffer
only, 50 µg/ml of blocking SR-BI IgG, or 50 µg/ml iso-
type-matched nonspecific IgG for 15 minutes at 37°C.
The cells were then incubated with 0.75 µCi/ml of
[3H]arginine and 10 µg/ml of female HDL for 15 min-
utes at 37°C. In addition, another set of cells was treat-
ed with 1 µg/ml of ionomycin to determine maximal
eNOS stimulation. Figure 2a demonstrates that female
HDL stimulated eNOS in cells pretreated with buffer
or nonspecific IgG. In contrast, cells pretreated with
blocking SR-BI IgG did not increase eNOS activity in
response to the addition of female HDL. To further
ensure that the stimulation of eNOS required the asso-
ciation of female HDL with SR-BI, we used male HDL
in a standard competition experiment. HME cells were
incubated with 0.75 µCi/ml of [3H]arginine, 10 µg/ml
of female HDL, and increasing amounts of male HDL.
Figure 2b demonstrates that excess male HDL was able
to compete for the ability of female HDL to stimulate
eNOS activity. Male and female HDL did not affect ion-
omycin-induced eNOS activity (data not shown).
HDL-associated estradiol is responsible for eNOS stimula-
tion. We hypothesized that estradiol associated with
female HDL may be responsible for the stimulation of
eNOS. To test this possibility, we quantified (34) the
amount of estradiol associated with HDL isolated from
men and women. Table 1 demonstrates that HDL iso-
lated from women or female mice contained estradiol,
whereas HDL isolated from men or male mice did not
contain detectable amounts of estradiol. To determine
if HDL-associated estradiol was responsible for the
ability of female HDL to stimulate eNOS, we isolated
HDL from C57BL/6 female mice that were intact, had
their ovaries removed, or had their ovaries removed and
a 17-β-estradiol pellet implanted to deliver physiologi-
cal levels of estradiol (34). Intact animals had plasma
estradiol levels of 29 ± 12 pg/ml, ovariectomized ani-
mals had plasma estradiol levels of less than 5 pg/ml
(the detection limit is approximately 5 pg/ml), and
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Figure 2
The ability of female HDL to stimulate eNOS requires binding to SR-BI.
(a) Human microvascular endothelial cells were pretreated with
buffer only, 50 µg/ml of blocking SR-BI IgG, or 50 µg/ml isotype-
matched nonspecific IgG for 15 minutes at 37°C. The cells were then
incubated with 0.75 µCi/ml of [3H]arginine and 10 µg/ml of female
HDL or 1 µg/ml of ionomycin for 15 minutes at 37°C. The cells were
processed to quantify the amount of citrulline generated. Each exper-
iment included controls, using 1 mM L-NNA to demonstrate that
over 99% of the generated citrulline was due to eNOS activity (data
not shown). The data are from six independent experiments, with
triplicate measurements in each experiment (mean ± SE). (b) Human
microvascular endothelial cells were pretreated with 0.75 µCi/ml of
[3H]arginine and then incubated with 10 µg/ml of female HDL or
increasing concentrations of male HDL for 15 minutes. The amount
of citrulline generated was then quantified. Each experiment includ-
ed controls, using 1 mM L-NNA to demonstrate that over 99% of the
generated citrulline was due to eNOS activity (data not shown). The
data are from six independent experiments, with triplicate measure-
ments in each experiment (mean ± SE).
Table 1
The quantification of estradiol
Human Human Mouse Mouse OVX OVX Male Male HDL LDL BSA
female HDL male HDL female HDL male HDL + E2 + E2 + E2 + E2 + E2
Estradiol/HDL 0.024 ± ND 0.015 ± ND ND 0.019 ± 0.012 ± 0.020 ± 0.018 ± 0.021 ±
(pg/mg) 0.004 0.002 0.003 0.004 0.004 0.003 0.005
Estradiol was quantified as described in the Methods. Each value represents four independent experiments, with triplicate measurements in each experiment
(mean ± SE). ND, not detectable.
ovariectomized animals containing an estradiol pellet
had plasma estradiol levels of 31 ± 13 pg/ml. Impor-
tantly, estradiol could not be detected in HDL isolated
from ovariectomized animals, whereas HDL isolated
from ovariectomized animals receiving estradiol had
levels similar to those of intact animals (Table 1).
Determination of the ability of these HDLs to stimu-
late eNOS in HME cells was performed as described
above. HDL isolated from intact mice stimulated
eNOS to the same extent as the ionomycin control (Fig-
ure 3a). In contrast, HDL isolated from ovariectomized
animals did not stimulate eNOS. The restoration of
plasma and HDL estradiol levels in ovariectomized ani-
mals with an estradiol pellet restored the ability of iso-
lated HDL to stimulate eNOS.
The ovariectomy studies strongly suggested that the
estradiol associated with HDL was responsible for the
stimulation of eNOS. To further test this possibility,
male mice were implanted with estradiol pellets to
increase the plasma level of estradiol to that of female
mice (35 ± 9 for male mice versus 29 ± 12 pg/ml for
female mice). HDL isolated from these mice stimulated
eNOS nearly as well as HDL isolated from intact female
mice (Figure 3a). In addition, when HDL isolated from
untreated male mice was enriched with estradiol in
vitro, this HDL maximally stimulated eNOS (Figure 3a),
further suggesting that estradiol is the HDL component
responsible for the activation of eNOS. In contrast, LDL
and BSA enriched with comparable amounts of estra-
diol did not stimulate eNOS, indicating that estradiol
needed to be associated with HDL to stimulate eNOS
(Figure 3a). For all of the in vitro studies, the HDL, LDL,
or BSA was reisolated after enriching in estradiol, and
the amount of estradiol associated was quantified
(Table 1). The nonactive stereoisomer of 17-β-estradiol,
17-α-estradiol, did not stimulate eNOS under any con-
ditions tested (data not shown), further suggesting that
activation was due to 17-β-estradiol and not some other
HDL component. To further ensure that estradiol was
the component of HDL responsible for eNOS stimula-
tion, the ability of these HDLs to stimulate eNOS in
HME cells was determined in the presence of the pure
estrogen receptor antagonist ICI 182,780 (10 µM) (36).
The estrogen receptor antagonist did not affect iono-
mycin-mediated eNOS stimulation but completely
inhibited HDL-mediated stimulation of eNOS (Figure
3b), further implicating estradiol.
The data suggest that HDL delivers estradiol to the
cells in an SR-BI–dependent manner, which subse-
quently stimulates eNOS. To determine if HDL is capa-
ble of delivering estradiol to the cells, we labeled male
HDL with 125I (labels the protein) and [3H]estradiol. Var-
ious concentrations of this double-radiolabeled HDL
were then incubated with human microvascular
endothelial cells for 15 minutes and processed to deter-
mine the amount of 125I and 3H associated with the cells.
Table 2 demonstrates that 125I-labeled HDL associated
with the cells and that the association was linear with
respect to the concentration of HDL. In contrast, the
amount of [3H]estradiol associated with the cells
increased rapidly and was not linear with respect to the
concentration of HDL. Importantly, the SR-BI blocking
antibody prevented the association of both 125I and 3H
with the cells. These data are similar to those seen when
measuring the selective uptake of cholesteryl ester from
HDL particles — namely, the amount of radiolabeled
sterol associated with cells is much greater than can be
accounted for by the association of HDL particles with
SR-BI on the cell surface (37). These data demonstrate
that even at low concentrations of HDL, enough HDL
can associate with SR-BI to deliver estradiol to the cells.
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Figure 3
HDL-associated estradiol is responsible for eNOS stimulation. (a)
HDL was isolated from female C57BL/6 mice that had intact ovaries
(Intact), had the ovaries removed (OVX), or had the ovaries removed
and a 17-β-estradiol pellet implanted (OVX + E2). HDL was also iso-
lated from male age-matched C57BL/6 mice that had a 17-β-estra-
diol pellet implanted (Male + E2). In addition, HDL from control
male mice was isolated and enriched with 17-β-estradiol in vitro
(Male HDL + E2). LDL from female mice (LDL + E2) and BSA (BSA
+ E2) were also enriched with 17-β-estradiol in vitro. The in
vitro–modified HDL, LDL, and BSA were reisolated, and the amount
of estradiol associated was quantified before use (see Methods).
Human microvascular endothelial cells were pretreated with 0.75
µCi/ml of [3H]arginine, followed by treatment with 10 µg/ml of each
sample or 1 µg/ml of ionomycin for 15 minutes at 37°C. The cells
were then processed to quantify the amount of citrulline generated.
Each experiment included controls, using 1 mM L-NNA to demon-
strate that over 99% of the generated citrulline was due to eNOS
activity (data not shown). The data are from eight independent
experiments, with triplicate measurements in each experiment (mean
± SE). (b) The same assay as described above was used, with the
exception that 10 µM of ICI 182,780 was added to each of the reac-
tions. The data are from four independent experiments, with tripli-
cate measurements in each experiment (mean ± SE).
Female HDL promotes vessel relaxation. The data present-
ed thus far demonstrate that HDL-associated estradiol
promotes the stimulation of eNOS in human microvas-
cular endothelial cells in an SR-BI–dependent manner.
We next determined if the differential effects of female
and male HDL on eNOS activity translated into the abil-
ity of these HDLs to stimulate relaxation of the femoral
artery. Arteries from C57BL/6 mice were obtained and
processed to measure the degree of relaxation (35). The
vessels were precontracted with 30 nM 5-hydroxytrypta-
mine and then incubated with various concentrations of
HDL isolated from female (Figure 4a, representative
trace) and male (Figure 4b, representative trace) mice.
Approximately 0.015 pg of estradiol was associated with
1 µg of female HDL as determined by a radioim-
munoassay (34), whereas estradiol associated with male
HDL was not detectable. HDL isolated from female mice
caused a dose-dependent relaxation of the vessel with a
maximal response at 1 µg/ml of HDL. Acetylcholine (1
µM) induced the same extent of relaxation as 1 µg/ml of
HDL (data not shown and Figure 5a). In contrast, HDL
isolated from males did not promote significant relax-
ation, even when used at a 10-fold higher concentration
than HDL isolated from females (Figure 4b). Figure 4c is
the quantification of vessel relaxation from all of the ani-
mals and individual muscle strips. The inclusion of 1
mM L-NNA, an eNOS inhibitor, in the relaxation assay
inhibited the ability of acetylcholine or female HDL to
induce maximal relaxation (data not shown).
We next used femoral arteries isolated from
C57BL/6 mice (wild type) and SR-BI null mice to
determine if female HDL was indeed inducing
vasorelaxation in an SR-BI–dependent manner.
Acetylcholine (1 µM) induced similar relaxation in
arteries isolated from C57BL/6 and SR-BI null mice
(Figure 5). In contrast, HDL isolated from female
mice did not relax the arteries isolated from SR-BI
null mice, although the same HDL preparation
induced relaxation in arteries isolated from C57BL/6
mice (Figure 5a). These data demonstrate that female
HDL requires the presence of SR-BI to induce relax-
ation of isolated femoral arteries. Finally, we denud-
ed the femoral arteries isolated from C57BL/6 mice
of endothelial cells to determine if the relaxation was
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Table 2
Quantification of double-labeled HDL (125I and [3H]estradiol) associated with human microvascular endothelial cells
HDL labeled with 125I 0.01 µg 0.05 µg 0.1 µg 0.5 µg 1.0 µg 10.0 µg
and [3H]estradiol
125I DPMs 1,103 ± 213 5,165 ± 345 9,873 ± 1,089 33,514 ± 4,106 57,286 ± 5,638 83,663 ± 6,630
125I DPMs plus 20 ± 6 23 ± 7 35 ± 5 59 ± 18 75 ± 27 82 ± 31
blocking SR-BI IgG
3H DPMs 326 ± 213 3,462 ± 345 64,500 ± 3,959 512,874 ± 11,004 517,254 ± 9,291 526,877 ±12,655
3H DPMs plus 12 ± 6 13 ± 5 18 ± 12 22 ± 16 24 ± 9 32 ± 11
blocking SR-BI IgG
Male HDL was labeled as described in the Methods. The HDL was added to human microvascular endothelial cells for 15 minutes at 37°C. Where indicated,
50 µg/ml of blocking SR-BI IgG was also added. The cells were washed four times in PBS, and the amount of 125I and 3H associated with the cells was deter-
mined. Each value represents four independent experiments, with triplicate measurements in each experiment (mean ± SE). DPM, disintegrations per minute.
Figure 4
Female HDL but not male HDL potently relaxes arterial contraction.
Femoral artery strips from wild-type C57BL/6 mice were precon-
tracted with 30 nM 5-hydroxytryptamine (5-HT), and cumulative
concentrations of HDL, isolated from female (a) or male (b) mice,
were added (indicated by arrow). In each single strip, HDL purified
from both female and male mice was tested. The order of applica-
tion of the female HDL versus the male HDL did not affect the
results. Note that addition of 1 µM acetylcholine (ACh) caused nor-
mal relaxation in the same muscle strip in which the HDL purified
from male mice did not cause detectable relaxation. (c) Quantifica-
tion of the extent of relaxation caused by HDL purified from female
or male mice. Six muscle strips from three mice were used.
endothelium dependent. Both acetylcholine and
female HDL induced relaxation on arteries contain-
ing an intact endothelium (Figure 5b). In contrast,
arteries that did not have an intact endothelium did
not respond to acetylcholine or female HDL (Figure
5b), demonstrating that the relaxation is endotheli-
um dependent. In addition, the inclusion of 1 mM 
L-NNA, an eNOS inhibitor, in the relaxation assay
inhibited the ability of acetylcholine or female HDL
to induce maximal relaxation (data not shown).
Estrogen replacement therapy restores the capability of HDL
to stimulate eNOS. The above data were generated with
HDL isolated from reproductive-competent mice and
humans. If our overall hypothesis is correct, then HDL
isolated from postmenopausal women should not
stimulate eNOS, and HDL isolated from post-
menopausal women receiving estrogen replacement
therapy should stimulate eNOS. To test this, we isolat-
ed HDL from five premenopausal women, five post-
menopausal women, and five postmenopausal women
receiving estrogen replacement therapy. The HDLs
were then used in our HME, live-cell eNOS assay sys-
tem as described above. The HDL isolated from pre-
menopausal women stimulated eNOS to the same
extent as the ionomycin control (Figure 6). In contrast,
HDL isolated from postmenopausal women did not
substantially stimulate eNOS (Figure 6). Finally, HDL
isolated from postmenopausal women receiving estro-
gen replacement therapy stimulated eNOS, although
the variability in the data was greater than that for pre-
menopausal women (Figure 6).
Discussion
The current data are the first to our knowledge to
demonstrate that female HDL but not male HDL iso-
lated from either mice or humans will stimulate eNOS
and promote the relaxation of femoral artery strips. Fur-
thermore, we demonstrated that the mechanism of
HDL-induced stimulation of eNOS is due to estradiol
associated with the lipoprotein. Importantly, the female
mouse HDL used in these studies contained only
approximately 0.015 pg of estradiol per microgram of
HDL, which is a concentration of estradiol that is with-
in physiological plasma levels. These studies illustrate
that male and female HDLs are not interchangeable and
that future mechanistic studies involving HDL will need
to distinguish between male and female HDL. In addi-
tion, the data suggest that HDL has a more active role
in regulating the cardiovascular system than previous-
ly appreciated. The data demonstrate that HDL and the
associated estradiol bind to a specific receptor, SR-BI,
and generate a signal that stimulates the production of
nitric oxide, thereby outlining a novel mechanism that
links plasma lipoprotein levels to endothelial function
and ultimately to cardiovascular disease.
Yuhanna et al. (4) have demonstrated that HDL will
stimulate eNOS; however, significantly higher concen-
trations of HDL were required than used in the present
studies. One possible reason for this difference in the
amount of HDL required for eNOS stimulation may be
because they used male or a combination of male and
female HDL. Our data demonstrate that male HDL can
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Figure 5
HDL-induced relaxation is SR-BI and endothelium dependent. (a)
Endothelium-intact femoral artery strips isolated from C57BL/6 or
SR-BI null mice were precontracted with 30 nM 5-hydroxytrypta-
mine. Acetylcholine (1 µM) or 10 µg/ml HDL purified from female
mice was then added to the tissue bath, and the extent of relaxation
was measured. Six muscle strips were used for each group. Black bars
represent C57BL/6 mice and white bars SR-BI null mice. (b)
Endothelium-intact or endothelium-denuded femoral artery strips
isolated from control C57BL/6 mice were precontracted with 30 nM
5-hydroxytryptamine. Acetylcholine (1 µM) or 10 µg/ml HDL puri-
fied from female mice was then added to the tissue bath, and the
extent of relaxation was measured. Three to six muscle strips were
used for each group. Black bars represent endothelium intact and
white bars endothelium denuded.
Figure 6
HDL isolated from women receiving estrogen replacement therapy
stimulates nitric oxide generation. HDL was isolated from five pre-
menopausal women, five postmenopausal women, and five post-
menopausal women on estradiol replacement therapy. Human
microvascular endothelial cells were pretreated with 0.75 µCi/ml of
[3H]arginine and then incubated with 10 µg/ml of the above HDL
for 15 minutes. The amount of citrulline generated was then quanti-
fied. Each experiment included controls, using 1 mM L-NNA to
demonstrate that over 99% of the generated citrulline was due to
eNOS activity (data not shown). The data for each HDL are shown,
and each value is the average of six measurements.
prevent the stimulating effect of female HDL on eNOS,
apparently by competing for binding to SR-BI. Impor-
tantly, male HDL enriched with estradiol, either in vivo
or in vitro, stimulated eNOS, which suggests that male
HDL does not have an endogenous inhibitor of eNOS
or that some component of female HDL, other than
estradiol, is responsible for eNOS stimulation. Anoth-
er important observation was that only HDL-associat-
ed estradiol stimulated eNOS; LDL- and BSA-associat-
ed estradiol was unable to stimulate eNOS. This latter
point is consistent with our hypothesis that HDL bind-
ing to SR-BI targets the delivery of estradiol to eNOS.
Work by Chambliss et al. (7) demonstrated that
estrogen receptors are found associated with caveolae
and that interaction of estrogen with its receptor
resulted in the stimulation of eNOS. Importantly,
these studies were done with isolated plasma mem-
branes and isolated caveolae, which precludes the pos-
sibility of a transcriptional activation mechanism. Our
current data are consistent with a nontranscriptional
eNOS activation mechanism, because maximal eNOS
stimulation occurs within 1 minute and is rapidly
reversed. However, it is unclear how estradiol and
estrogen receptor interactions stimulate eNOS.
Haynes et al. (29) have demonstrated that estradiol can
stimulate akt kinase, which can subsequently phos-
phorylate and stimulate eNOS; however, it has not
been demonstrated that estrogen receptors mediate
akt kinase activation. Alternatively, our laboratory has
demonstrated that HDL–SR-BI interactions will stim-
ulate eNOS by increasing intracellular ceramide (5).
Although it is tempting to speculate that HDL-associ-
ated estradiol stimulates ceramide production in an
estrogen receptor–dependent manner, this has not
been demonstrated. Dissecting the exact mecha-
nism(s) responsible for HDL-associated estradiol to
stimulate eNOS will require extensive additional stud-
ies and may provide a new paradigm for examining the
cardioprotective effects of HDL.
One of the interesting aspects of the current studies
is that HDL-associated estradiol stimulates eNOS in an
SR-BI–dependent manner at a concentration of HDL
that is below the apparent Kd of HDL binding to SR-BI.
However, the data demonstrate that female HDL stim-
ulates eNOS and muscle relaxation in a concentration-
and SR-BI–dependent manner. Liu and Krieger (37)
recently demonstrated that the Kd for HDL binding to
SR-BI was approximately 11 µg of protein per milliliter;
however, they demonstrated that the “uptake maxi-
mum” for cholesteryl ester was only about 106 ng of
protein per assay. These data suggest that only a frac-
tion of the SR-BI needs be bound to HDL to achieve the
maximum uptake of cholesteryl ester. Our data are
consistent with these findings. In addition, we (5, 21,
38) and others (4) have demonstrated that SR-BI is
highly enriched in caveolae in endothelial cells, and it
is possible that HDL–SR-BI interactions in caveolae
may differ from receptors not associated with caveolae.
For instance, caveolae can invaginate or vesiculate (39),
which would have the net result of decreasing the vol-
ume associated with the HDL–SR-BI interaction. This
putative mechanism would thereby increase the effec-
tive local concentration of HDL and may well bring it
close to the apparent Kd. SR-BI, estrogen receptors, and
eNOS are all localized to endothelial caveolae (40),
which potentially generates a unique environment to
directly deliver and concentrate the effects of estradiol
on eNOS. We do not know how estradiol stimulates
eNOS. The data suggest that an estrogen receptor is
involved, but it is unclear if the α, the β, or the recently
identified truncated receptor is involved. Furthermore,
we were unable to measure the effective local concen-
tration of estradiol associated with the putative caveo-
lae-signaling complex; however, it is presumably high-
er locally than would be expected if the estradiol was
randomly distributed throughout the cells. Finally, the
available data concerning estradiol stimulation of
eNOS suggest that it occurs through a signal trans-
duction mechanism that amplifies the initial input,
which further suggests that all of the SR-BI and/or
estrogen receptors need not be occupied to stimulate
eNOS activity and muscle relaxation. Future studies
will focus on the detailed molecular mechanisms that
allow low concentrations of HDL and estradiol to
stimulate eNOS.
Many studies have demonstrated that high plasma
HDL levels correlate with a decreased risk of cardiovas-
cular disease (14–16) and that women, before
menopause, are afforded more protection than men
(22–24). Our data suggest that one mechanism which
may contribute to the cardioprotection seen in pre-
menopausal women is the delivery of HDL-associated
estradiol directly to caveola-localized eNOS through
SR-BI. A critical test of this hypothesis was done using
HDL isolated from premenopausal women, post-
menopausal women, and postmenopausal women
receiving estrogen replacement therapy. In contrast to
HDL isolated from premenopausal women, HDL iso-
lated from postmenopausal women did not stimulate
eNOS. The levels of estradiol in serum from the post-
menopausal women were at the limit of detection and
comparable to that of men (data not shown). This
inability of HDL isolated from postmenopausal
women to stimulate eNOS correlates with the increase
in the risk of developing cardiovascular disease. How-
ever, HDL isolated from postmenopausal women
receiving estrogen replacement therapy was able to
stimulate eNOS, although to differing extents.
The current data are especially interesting because
the HERS trial (41) documented that estrogen replace-
ment therapy was not beneficial in preventing cardio-
vascular events in women with advanced atherosclero-
sis. Although the data demonstrate that replacement
of estradiol in women with established atherosclerosis
did not promote the regression of the lesions, it is
unclear what estradiol may be doing in women before
the establishment of lesions. The initiation of athero-
sclerotic lesion formation is complicated and involves
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multiple mechanisms, several of which can be influ-
enced by nitric oxide. The current study demonstrates
that in both humans and mice, estradiol replacement
will allow HDL to associate with estradiol and that this
HDL is able to stimulate eNOS. The mechanistic role
of how estradiol may function in preventing the initia-
tion and progression of atherosclerosis has not been
extensively studied. In summary, our data provide a
mechanistic outline of how HDL and estradiol may
function together to decrease the initiation and pro-
gression of atherosclerosis.
Acknowledgments
We thank William V. Everson for critically reading the
manuscript and providing intellectual input and the
Cardiovascular Research Group for invaluable advice
and assistance. This work was supported, in part, by a
COBRE grant (P20 RR15592) from the National Center
for Research Resources at NIH and by grants from the
National Heart, Lung, and Blood Institute (HL62844
and HL64056 to E.J. Smart and HL67284 to M. Gong).
1. Mendelsohn, M.E. 2002. Protective effects of estrogen on the cardiovas-
cular system. Am. J. Cardiol. 89:12E–17E.
2. Mendelsohn, M.E. 2000. Mechanisms of estrogen action in the cardio-
vascular system. J. Steroid Biochem. 74:337–343.
3. von Eckardstein, A., and Assmann, G. 2000. Prevention of coronary heart
disease by raising high-density lipoprotein cholesterol. Curr. Opin. Lipi-
dol. 11:627–637.
4. Yuhanna, I.S., et al. 2001. High-density lipoprotein binding to scavenger
receptor-BI activates endothelial nitric oxide synthase. Nat. Med. 7:853–857.
5. Li, X.-A., et al. 2002. High-density lipoprotein binding to scavenger
receptor class B, type I activates endothelial nitric oxide synthase in a
ceramide-dependent manner. J. Biol. Chem. 277:11058–11063.
6. Hisamoto, K., et al. 2001. Estrogen induces the akt-dependent activation
of endothelial nitric-oxide synthase in vascular endothelial cells. J. Biol.
Chem. 276:3459–3467.
7. Chambliss, K.L., et al. 2000. Estrogen receptor alpha and endothelial
nitric oxide synthase are organized into a function signaling module in
caveolae. Circ. Res. 87:E44–E52.
8. Chambliss, K.L., Yuhanna, I.S., Anderson, R.G., Mendelsohn, M.E., and
Shaul, P.W. 2002. ERβ has nongenomic action in caveolae. Mol.
Endocrinol. 16:938–946.
9. Rubbo, H., Trostchansky, A., Botti, H., and Batthyany, C. 2002. Interac-
tions of nitric oxide and peroxynitrite with low-density lipoprotein. Biol.
Chem. 383:547–552.
10. Laroux, F.S., et al. 2000. Role of nitric oxide in the regulation of acute
and chronic inflammation. Antioxid. Redox Signal. 2:391–396.
11. Lefer, A.M. 1997. Nitric oxide: nature’s naturally occurring leukocyte
inhibitor. Circulation. 95:553–554.
12. Li, H., and Forstermann, U. 2000. Nitric oxide in the pathogenesis of vas-
cular disease. J. Pathol. 190:244–254.
13. Taddei, S., Virdis, A., Ghiadoni, L., Salvetti, G., and Salvetti, A. 2000.
Endothelial dysfunction in hypertension. J. Nephrol. 13:205–210.
14. O’Connell, B.J., and Genest, J. 2001. High-density lipoproteins and
endothelial function. Circulation. 16:1978–1983.
15. Libby, P. 2001. Managing the risk of atherosclerosis: the role of high-den-
sity lipoprotein. Am. J. Cardiol. 20:3N–8N.
16. Tonkin, A. 2001. High-density lipoprotein cholesterol and treatment
guidelines. Am. J. Cardiol. 20:41N–44N.
17. Bruce, C., Chouinard, R.A., and Tall, A.R. 1998. Plasma lipid transfer pro-
teins, high-density lipoproteins, and reverse cholesterol transport. Annu.
Rev. Nutr. 18:297–330.
18. Sviridov, D., and Nestel, P. 2002. Dynamics of reverse cholesterol
transport: protection against atherosclerosis. Atherosclerosis.
161:245–254.
19. Trigatti, B., Rigotti, A., and Krieger, M. 2000. The role of the high-den-
sity lipoprotein receptor SR-BI in cholesterol metabolism. Curr. Opin.
Lipidol. 11:123–131.
20. Krieger, M. 2001. Scavenger receptor class B type I is a multiligand HDL
receptor that influences diverse physiologic systems. J. Clin. Invest.
108:793–797. doi:10.1172/JCI200114011.
21. Uittenbogaard, A., Shaul, P.W., Yuhanna, I.S., Blair, A., and Smart, E.J.
2000. High density lipoprotein prevents oxidized low density lipopro-
tein-induced inhibition of endothelial nitric-oxide synthase localization
and activation in caveolae. J. Biol. Chem. 275:11278–11283.
22. Matthews, K.A., Kuller, L.H., Sutton-Tyrrell, K., and Chang, Y.F. 2001.
Changes in cardiovascular risk factors during the perimenopause and
postmenopause and carotid artery atherosclerosis in healthy women.
Stroke. 32:1104–1111.
23. Cid, M.C., Schnaper, H.W., and Kleinman, H.K. 2002. Estrogens and the
vascular endothelium. Ann. N. Y. Acad. Sci. 966:143–157.
24. Langer, R.D. 2002. Hormone replacement and the prevention of cardio-
vascular disease. Am. J. Cardiol. 89:36E–46E.
25. Tolbert, T., and Oparil, S. 2001. Cardiovascular effects of estrogen.
Am. J. Hypertens. 14:186S–193S.
26. Sader, M.A., and Celermajer, D.S. 2002. Endothelial function, vascular
reactivity and gender differences in the cardiovascular system. Cardiovasc.
Res. 53:597–604.
27. Chambliss, K.L., and Shaul, P.W. 2002. Rapid activation of endothelial
NO synthase by estrogen: evidence for a steroid receptor fast-action com-
plex (SRFC) in caveolae. Steroids. 67:413–419.
28. Wyckoff, M.H., et al. 2001. Plasma membrane estrogen receptors are cou-
pled to endothelial nitric-oxide synthase through Gα(i). J. Biol. Chem.
276:27071–27076.
29. Haynes, M.P., et al. 2000. Membrane estrogen receptor engagement acti-
vates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in
human endothelial cells. Circ. Res. 87:677–682.
30. Davda, R.K., Chandler, L.J., Crews, F.T., and Guzman, N.J. 1993. Ethanol
enhances the endothelial nitric oxide synthase response to agonists.
Hypertension. 21:939–943.
31. Schumaker, V.N., and Puppione, D.L. 1986. Sequential flotation ultra-
centrifugation. In Plasma lipoproteins. Part A: preparation, structure, and
molecular biology. J.P. Segrest and J.J. Albers, editors. Academic Press, Inc.
Orlando, Florida, USA. 155–170.
32. Gwynne, J.T., and Mahaffee, D.D. 1989. Rat adrenal uptake and
metabolism of high density lipoprotein cholesteryl ester. J. Biol. Chem.
264:8141–8150.
33. Bilheimer, D.W., Eisenberg, S., and Levy, R.I. 1972. The metabolism of
very low density lipoprotein. Biochim. Biophys. Acta. 260:212–221.
34. Dubal, D.B., et al. 2001. Estrogen receptor α, not β, is a critical link in
estradiol-mediated protection against brain injury. Proc. Natl. Acad. Sci.
U. S. A. 98:1952–1957.
35. Gong, M.C., et al. 1992. Myosin light chain phosphatase activities and
the effects of phosphatase inhibitors in tonic and phasic smooth mus-
cle. J. Biol. Chem. 267:14662–14668.
36. Simoncini, T., et al. 2002. Genomic and nongenomic mechanisms of
nitric oxide synthase induction in human endothelial cells by a fourth-
generation selective estrogen receptor modulator. Endocrinology.
143:2052–2061.
37. Liu, B., and Krieger, M. 2002. Highly purified scavenger receptor class B,
type I reconstituted into phosphatidylcholine/cholesterol liposomes
mediates high affinity high density lipoprotein binding and selective
lipid uptake. J. Biol. Chem. 277:34125–34135.
38. Kincer, J.F., et al. 2002. Hypercholesterolemia promotes a CD36-depend-
ent and endothelial nitric oxide synthase-mediated vascular dysfunction.
J. Biol. Chem. 277:23525–23533.
39. Smart, E.J., et al. 1999. Caveolins, liquid-ordered domains, and signal
transduction. Mol. Cell. Biol. 19:7289–7304.
40. Shaul, P.W. 2002. Regulation of endothelial nitric oxide synthase: loca-
tion, location, location. Annu. Rev. Physiol. 64:749–774.
41. Grady, D., et al. 2002. Cardiovascular disease outcomes during 6.8 years
of hormone therapy: heart and estrogen/progestin replacement study
follow-up (HERS II). JAMA. 288:49–57.
The Journal of Clinical Investigation | May 2003 | Volume 111 | Number 10 1587
